Full-Time

Clinical Engagement Associate Director

Europe & Asia

Beeline Medicines

Beeline Medicines

51-200 employees

Clinical-stage biotech developing precision autoimmune therapies

Compensation Overview

€110k - €140k/yr

+ Annual bonus + Long-term incentive/equity award

Germany

Remote

Field-based within the assigned territory, with regular travel and potential travel outside the territory.

Bachelor's, Master's

Category
Biology & Biotech (1)
Required Skills
Veeva
CRM

Get referred to Beeline Medicines

See people who can refer or advise you

Requirements
  • A bachelor’s degree in a scientific or related discipline.
  • 10+ years of experience in clinical operations, clinical development, clinical research, or a field-based clinical engagement role within the pharmaceutical or biotechnology industry.
  • 3+ years of direct people management experience.
  • Demonstrated experience leading, coaching, and developing field-based or matrixed teams, managing investigator relationships, and supporting clinical trial site activation and enrollment.
  • Experience collaborating with contract research organizations, investigative sites, field medical teams, and human resources or talent partners, including medical science liaison partnerships.
  • Strong scientific and clinical knowledge of immunology and inflammation, including disease biology, standard of care, clinical trial design considerations, and the competitive clinical research landscape across relevant indications.
  • Expertise in clinical trial site management and investigator engagement strategy, including site feasibility assessment, investigator identification and qualification, site initiation support, and enrollment optimization.
  • Familiarity with clinical operations tools including clinical trial management systems, customer relationship management platforms such as Veeva, and site management systems, with experience overseeing team documentation of field activities to good clinical practice and compliance standards.
  • Ability to manage and develop a team of field-based professionals independently, prioritize team objectives strategically, and operate with minimal supervision across a broad geography.
  • Ability to translate team and field observations into actionable insights and coaching that improve program strategy, site selection, and enrollment performance.
  • Ability to engage team members in substantive performance and development conversations and discuss the company pipeline, protocol design, and immunology and inflammation disease areas with investigators when needed.
  • Ability to provide concise, actionable team performance and field intelligence updates to Clinical Operations, Clinical Development, and Medical Affairs leadership through regular written and verbal reporting.
  • Ability to represent the company’s science and organizational values at investigator meetings, scientific conferences, and site visits.
  • Ability to navigate complex stakeholder environments and communicate effectively with team members, academic physicians, research coordinators, site administrators, and institutional review board contacts.
  • Ability to travel 70% or more as needed, including occasional overnight stays.
  • Ability to work evenings and weekends as needed for physician or patient events, both in person and virtually.
  • Depending on geography, ability to manage a multi-state territory with a diverse customer base.
Responsibilities
  • Provide day-to-day people leadership for a team of Clinical Engagement Leads, including coaching, performance management, goal-setting, and career development.
  • Translate clinical program goals into team-level objectives for investigator identification, site feasibility, activation, and enrollment performance in the assigned region or country.
  • Recruit, onboard, and develop Clinical Engagement Lead talent in partnership with Human Resources and Clinical Operations leadership.
  • Review and approve site engagement plans and feasibility recommendations, providing strategic input on site selection, activation timelines, and enrollment risk mitigation.
  • Serve as the escalation point for complex investigator and site relationship issues and partner with Clinical Operations, Clinical Development, and Medical Affairs leadership to resolve challenges.
  • Consolidate and communicate team-level field intelligence, enrollment trends, and performance metrics to senior leadership in a structured, actionable manner.
  • Partner with Clinical Development, Medical Affairs, and Human Resources leaders to ensure team alignment, appropriate resourcing, and consistent application of company policies.
  • Support development of team training, onboarding, and engagement playbooks for Clinical Engagement Leads.
  • Oversee team contributions to investigator-initiated study identification and evaluation in coordination with Medical Affairs.
  • Oversee data quality and compliance of investigator interactions, site assessments, and clinical engagement activities recorded by the team in the customer relationship management system.
  • Perform other duties and responsibilities as assigned.
Desired Qualifications
  • An advanced degree, such as a Master of Science or Master of Public Health, in a relevant clinical, biomedical, or pharmaceutical sciences discipline.

Beeline Medicines is a clinical-stage biotechnology company focused on precision therapies for autoimmune and inflammatory diseases, formed after in-licensing five programs from Bristol Myers Squibb with a $300 million Series A led by Bain Capital. Its lead programs include afimetoran, an oral lupus therapy that inhibits TLR7 and TLR8, lomedeucitinib, an allosteric TYK2 inhibitor, and two IND-stage biologics targeting IL-18 and IL-10 pathways. The drugs work by modulating specific immune signaling pathways to reduce inflammation, with afimetoran designed to address lupus drivers. The company differentiates itself by using in-licensed assets from a major pharma partner and combining them with an experienced leadership team to push multiple programs toward pivotal trials, starting with Phase 2 for afimetoran targeted for late 2026.

Company Size

51-200

Company Stage

Series A

Total Funding

$426.3M

Headquarters

Stamford, Connecticut

Founded

2025

Get referred to Beeline Medicines

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Beeline closed a $126.3 million extension on June 30, 2026, reaching $426.3 million.
  • FDA Fast Track for afimetoran in May 2025 accelerates regulatory interaction.
  • Management plans several clinical starts within 12 months, expanding catalysts beyond lupus.

What critics are saying

  • Afimetoran’s Phase 2 lupus readout in H2 2026 is the company’s make-or-break catalyst.
  • Failure versus Benlysta, Saphnelo, and competing lupus drugs kills the pivotal plan.
  • Five BMS-origin assets concentrate scientific risk; one bad readout can crush financing appetite.

What makes Beeline Medicines unique

  • BMS licensed five programs to Beeline in 2025, de-risking discovery.
  • Afimetoran targets TLR7/8, an upstream lupus mechanism unlike downstream cytokine biologics.
  • Saqib Islam and SpringWorks veterans bring repeatable biotech execution and exit experience.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Paid Vacation

Paid Holidays

Health Insurance

Company Equity

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-8%

1 year growth

-8%

2 year growth

-8%
Beeline Medicines
Jun 30th, 2026
Terms of Use - Beeline Medicines

Terms of Use Agreement Effective: April 8, 2026 1. Acceptance of the Terms and Conditions. Beeline Medicines Corporation (herein referred to as “Beeline,” “we,” “us” or “our”) provides and makes available this web site (the “Web Site”). All use of the Web Site is subject to the terms and conditions contained in this Terms of […]

Fierce Biotech
Jun 29th, 2026
BMS-backed Beeline raises $126M series A extension for autoimmune programs

Beeline Medicines has raised $126.3 million in a Series A extension, just two and a half months after emerging from stealth with $300 million in funding and five autoimmune programmes from Bristol Myers Squibb. The biotech startup, backed by BMS, is developing treatments targeting autoimmune diseases. The additional funding comes as the company rapidly advances its pipeline following its December debut. Details about the extension round's investors and the company's specific plans for the new capital were not disclosed.

Yahoo Finance
Apr 15th, 2026
Beeline debuts with $300M and immune drugs licensed from Bristol Myers

Beeline Medicines emerged from stealth with $300 million in Series A funding from Bain Capital to develop precision therapies for immune diseases. The company's pipeline includes five experimental medicines licensed from Bristol Myers Squibb nearly a year ago. Beeline's lead asset is afimetoran, a daily oral treatment for systemic lupus erythematosus targeting immune system receptors. A Phase 2 study is expected to complete in the second half of this year, with a pivotal programme planned thereafter. The pipeline also includes candidates for atopic dermatitis, lupus and plaque psoriasis, plus two preclinical assets. Saqib Islam, former CEO of SpringWorks Therapeutics, leads the company. Bain Capital previously backed Cerevel Therapeutics, acquired by AbbVie for nearly $9 billion, and Aiolos Bio, purchased by GSK.

Dealroom.co
Apr 15th, 2026
Beeline Medicines company information, funding & investors

Beeline Medicines, precision therapies for autoimmune and inflammatory diseases. Here you'll find information about their funding, investors and team.

GlobeNewswire
Apr 15th, 2026
Beeline Medicines Debuts to Deliver Category-Leading Precision Therapies for People Living with Autoimmune and Inflammatory Diseases

– Advancing a broad portfolio designed to deliver multiple paradigm-shifting therapies for devastating and underserved immune-mediated diseases –  – Lead...